Limitations in application of imanitib in hematologic malignancies: are there new principal solutions?


Cite item

Full Text

Full Text

Ограничения в применении иматиниба в онкогематологии: возможны ли новые принципиальные решения?. -
×

About the authors

O A Rukavitsyn

V P Pop

References

  1. Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
  2. Nowell P. C., Hungerford D. A. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
  3. Cortez D., Kadlec L., Pendergast A. M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 1995; 15: 5531-5541.
  4. Deininger M. W. N., Goldman J. M., Melo J. V. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
  5. Hehlmann R., Berger U., Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann. Hematol. 2005; 84: 487-497.
  6. Hehlmann R., Heimpel H., Hasford J. et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.
  7. Talpaz M., Kantarjian H. M., McCredie К. B. et al. Clinical investigation of human alpha-interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280-1288.
  8. O'Dwyer M. Multifaceted approach to the treatment of Bcr-Abl-Positive leukemias. Oncologist 2002; 7: 30-38.
  9. Kantarjian H., O'Brien S., Anderlini P. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87: 3069-3081.
  10. Huff C. A., Matsui W. H., Smith B. D., Jones R. J. The paradox of response and survival in cancer therapeutics. Blood 2006; 107: 431-434.
  11. Ravandi F., Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin. Cancer Res. 2006; 12 (2): 340-344.
  12. Dingli D., Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006; 24: 2603-2610.
  13. Allan N. C., Richards S. M., Shepherd P. C. UK Medical Research Council randomized, multicenter trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
  14. Ohnishi K., Ohno R., Tomonaga M. et al. A randomized trial comparing interferon-alpha with busulphan for newly diagnozed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906.
  15. Angstreich G. R., Matsui W., Huff C. A. et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br. J. Haematol. 2005; 130: 373-381.
  16. Pierce A., Smith D. L., Jakobsen L. V. et al. The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells. Hematol. J. 2001; 2: 257-264.
  17. Druker B. J., Tamura S., Buchdunger E. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 1996; 2: 561-566.
  18. Druker B. J., Talpaz M., Resta D. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344: 1031-1037.
  19. Druker B. J., Sawyers C. L., Kantarjian H. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001; 344: 1038-1042.
  20. Kantarjian H., Sawyers C., Hochhaus A. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 2002; 346: 645-652.
  21. Talpaz M., Silver R. Т., Druker B. J. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
  22. Sawyers C. L., Hochhaus A., Feldman E. et al. Gleevec/GlivecTM (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
  23. Ottmann O. G., Druker B. J., Sawyers C. L. et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
  24. O'Brien S., Guilhot F., Larson R. et al. The IRIS study: International randomized study of interferon and low-dose ara-C versus STI571 (imatinib) in patients with newly-diagnosed chronic phase chronic myeloid leukemia. N. Engl. J. Med. 2003; 348: 994-1004.
  25. von Bubnoff N., Schneller F., Peschel C., Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia chromosome positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-491.
  26. Hochhaus A., Kreil S., Corbin A. S. et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
  27. Azam M., Latek R. R., Daley G. Q. Mechanisms of autoinhibition and STI571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831-843.
  28. Goldman J., Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leukemia Lymphoma 2006; 47(1): 1-7.
  29. Hochhaus A., La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321-1331.
  30. Shah N. P., Nicoll J. M., Nagar B. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
  31. Branford S., Rudzki Z., Walsh S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-283.
  32. Corbin A. S., Rosee P. L., Stoffregen E. P. et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611-4614.
  33. Kantarjian H. M., Talpaz M., Giles F. et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med. 2006; 145: 913-923.
  34. Shah N. P., Tran C., Lee F. Y. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
  35. О'Hare Т., Walters D. K., Stoffregen E. P. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinibresistant Abl kinase domain mutants. Cancer Res. 2005; 65: 4500-4505.
  36. Hochhaus A., Kantarjian H. M., Baccarani M. et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2309.
  37. Weisberg E., Manley P. W., Breitenstein W. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
  38. Burgess M. R., Skaggs B. J., Shah N. P. et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. USA 2005; 102: 3395-3400.
  39. Kimura S., Naito H., Segawa H. et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948-3954.
  40. Puttini M., Coluccia A. M. L., Boschelli F. et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl Inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006; 66: 11314-11322.
  41. Gumireddy K., Baker S. J., Cosenza S. C. et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA 2005; 102: 1992-1997.
  42. Young M. A., Shah N. P., Chao L. H. et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680. Cancer Res. 2006; 66: 1007-1014.
  43. Samanta A. K., Lin H., Sun T. et al. Janus Kinase 2: A critical target in chronic myelogenous leukemia. Cancer Res. 2006; 66: 6468-6472.
  44. Tseng P. H., Lin H. P., Zhu J. et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 2005; 105: 4021-4027.
  45. Kantarjian H. M., O'Brien S. M., Keating M. et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997; 11: 1617-1620.
  46. Nimmanapalli R., О'Bryan E., Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers bcr-abl levels and induces apoptosis and differentiation of bcr-abl positive human leukemic blasts. Cancer Res. 2001; 61: 1799-1804.
  47. Peters D. G., Hoover R. R., Gerlach M. J. et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001; 97: 1404-1412.
  48. Gatto S., Scappini В., Pham L. et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in BSR/ABL-positive cells lines sensitive and resistant to imatinib mesilate. Haematologica 2003; 88: 853-863.
  49. Wassmann В., Pfeifer H., Scheuring U. J. et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib mesylate (Glivec). Blood 2004; 103: 1495-1498.
  50. Lee S., Kim Y. J., Min С. K. et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 2005; 105: 3449-3457.
  51. Savage D. G., Antmann К. H. Imatinib mesylate - a new oral targeted therapy. N. Engl. J. Med. 2002; 346: 683-693.
  52. Cools J., DeAngelo D. J., Gotlib J. et al. A tyrosine kinase created by fusion of the PDGFA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003; 348: 1201-1214.
  53. Rubin B. P., Singer S., Tsao С. et al. KIT activation is a ubiquitous feture of Most gastrointestinal stromal tumors. Cancer Res. 2001; 61: 8118-8121.
  54. Demetri G. D., von Mehren M., Blanke С D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347: 472-480.
  55. Heinrich M. C., Corless C. L., Demetri G. D. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21: 4342-4349.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies